atherosclerotic cardiovascular disease with elevated triglycerides
Cardiovascular · 2023–2024
2decisions
1medicine
2carried consumer input
0individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| icosapent ethyl Treatment of patients with atherosclerotic cardiovascular disease (ASCVD) and elevated triglycerides (≥1.7 mmol/L and <5.6 mmol/L) who are receiving statin… | Mar 2024 | Recommended with restriction | input received |
| icosapent ethyl Treatment of patients with established atherosclerotic cardiovascular disease (ASCVD) and elevated triglycerides (≥1.7 mmol/L and <5.6 mmol/L) with LDL… | Nov 2023 | Not recommended | input received |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 2 of 2 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.